In 2002, brevetoxin was confirmed to be produced by the raphidophytes C. marina and Chattonella antiqua (Haque and Onoue 2002) , and samples from mid-Atlantic waters containing Chattonella species have been reported to contain brevetoxin (Bourdelais et al. 2002) . The broad distribution of raphidophytes opens the concern of a widespread occurrence of this family of toxins.
Brevetoxins are analyzed largely to assure shellfish safety and on an as-needed basis for marine mammal and human intoxications. In the Gulf of Mexico, substantial monitoring is conducted for the causative organism, K. brevis, to prevent the harvest of contaminated shellfish beds. At present, toxin detection is conducted by the mouse bioassay (Delaney 1985) ; however, several functional assays are employed as potential alternatives to the mouse bioassay . In the case of marine mammal and human intoxications, brevetoxin has been detected in isolated cases by functional assays and liquid chromatography-mass spectrometry (LC-MS) in tissues from bottlenose dolphins (Mase et al. 2000) and West Indian manatees (Landsberg and Steidinger 1997) and in urine from intoxicated humans (Poli et al. 2000) .
A critical need exists for a simple and reliable detection method that can be used to routinely monitor aquatic animals and humans for brevetoxins. Fairey et al. (2001) described the application of a blood collection card method (Adam et al. 2000) to facilitate sampling and processing of blood samples from brevetoxin-exposed animals. The method of Fairey et al. (2001) uses a microplate receptorbinding assay (RBA) to screen samples for brevetoxin-like activity and LC-MS to confirm the presence of brevetoxin. In this article, we describe a brevetoxin radioimmunoassay (RIA) that we developed using a format parallel to the RBA, and compare the methods for detection of brevetoxin in the blood of exposed animals. We have determined that the RIA provides greater sensitivity and allows detection of blood brevetoxin at nonsymptomatic doses and for longer times postexposure.
Materials and Methods
Brevetoxin mouse exposure. For the short-term study and the dose response, female ICR mice, 18-20 g, were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA). The mice were kept for 24 hr with food and water given ad libitum. The mice were injected intraperitoneally (IP) with the brevetoxin congener PbTx-3 in phosphate-buffered saline (PBS) at 180 µg/kg body weight (bw) for the 24-hr study and at 10-300 µg/kg bw for the dose response. The control mice were injected with 1.66% methanol in PBS. The behavior and symptomatology of the mice were recorded for both studies. The blood was collected after 0.5, 1, 2, 4, and 24 hr for the short-term study, and after 1 hr for the dose response. At each time point or PbTx-3 concentration, four mice were anesthetized with 2.0 mg ketamine (ParkeDavis, Morris Plains, NJ, USA) and 0.2 mg Prom ACE (Aveco, Fort Dodge, IA, USA) in a volume of 100 µL PBS. The mice were then exsanguinated via cardiac puncture to the left ventricle with a lithium heparinized 1-cc syringe. We applied 100 µL of blood to each spot on the blood spot collection card. For the long-term study we used female CD-1 mice (Charles River Laboratories, Raleigh, NC, USA); the procedure used for treatment of these animals was previously described by Gordon et al. (2001) . Blood collection. Blood (100 µL) was applied to each circle on the grade-903 filterpaper blood collection card (Schleicher & Schuell, Keene, NH, USA). The cards were then allowed to dry overnight in a cool, dark environment. Once the cards were dry, they were separated by 6-in. × 6-in. weighing paper (VWR Scientific Products, Suwanee, GA, USA) and transferred to airtight plastic bags (VWR Scientific Products) containing desiccant packages (Multisorb Technologies Inc., Buffalo, NY, USA) and humidity cards (Multisorb Technologies Inc.). The cards were stored at -20°C until use.
Brevetoxin extraction from blood collection cards. The dried blood spots were prepared and processed the same way for both the RIA and the RBA. The entire 100 µL dried blood spot was cut from the cellulose blood collection card and extracted overnight in 2 mL methanol in a 12 × 75 mm test tube. The spots were removed from the tubes, and the methanol extracts were brought to dryness with nitrogen using a Turbovap LV evaporator (Zymark, Hopkinton, MA, USA) and then stored at -20°C until use. The blood spot extracts were resuspended in the original spot volume of 100 µL containing 90 µL RIA or RBA assay buffer and 10 µL methanol. Whole mouse blood (Harlan Bioproducts, Indianapolis, IN, USA) was used for blood spots spiked with 20 nM PbTx-3 (Calbiochem, San Diego, CA, USA), which were used as a quality check.
Immunizations. Groups of four sheep were immunized with PbTx-2 conjugated to ovalbumin and fetuin. For primary immunizations, immunogens were prepared as water-inoil suspensions by injecting the conjugate, dissolved in PBS (1 mg protein in 1 mL), into 2 mL Freund's complete adjuvant, followed by vortex mixing. Immunogens for secondary and subsequent immunizations (up to eight boosts) were administered as emulsions in Freund's incomplete adjuvant.
The immunogen emulsion (0.5 mL) was administered intramuscularly into the semitendinosus muscle, 0.25 mL per hind leg, via a 20-gauge needle. Test bleeds (10 mL Vacutainer, no. 366430; Becton Dickinson, Franklin Lakes, NJ, USA) were taken from the jugular vein 14 days after the third and subsequent immunizations, and antibody titers were determined by enzyme-linked immunosorbent assay (ELISA). Larger volumes of blood for antiserum production were obtained by venipuncture and collected into blood bags (Blood bag no. 4R0001; Baxter, Deerfield, IL, USA) under negative pressure, from sheep identified as having high titers. A series of three injections at 4-week intervals was followed by a rest period, with subsequent boosts at no less than 4-week intervals.
Antiserum from animal 7098, immunized with PbTx-2-fetuin conjugate, was chosen for use in the development of both the ELISA and the RIA because of its high antibody titer and competitive binding of both free PbTx-2 and the PbTx-protein conjugates. All animal manipulations were performed under the authority of the AgResearch Ruakura Animal Ethics Committee.
Radioimmunoassay. RIAs were run in 12 × 75 borosilicate glass tubes in PBS containing 137 mM NaCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , and 2.7 mM KCl (all from Sigma Chemical Company, St. Louis, MO, USA), and 0.01% Emulphor-EL 620 (GAF, New York, NY, USA. The assay tubes consisted of PbTx-3 standard or blood spot extract (50 µL), anti-PbTx antiserum (1:4,000), and [ 3 H]-PbTx-3 (0.4 nM) in PBS (final assay volume of 500 µL). The six PbTx-3 standards ranged from 0.01 nM to 100 nM. The PbTx-3 standards and blood spot extracts were allowed to preincubate in buffer at room temperature with the anti-PbTx-3 antibody for 1 hr before the [ 3 H]-PbTx-3 tracer was added. The tubes were placed on a shaker (Titramax 100; Heidolph Instruments, Cinnaminson, NJ, USA) and incubated for another hour after the addition of the radioactive toxin. Sac-Cel (Alpco Diagnostics, Windham, NH, USA) was then added to the assay tubes to allow for the separation of bound and unbound brevetoxin. The Sac-Cel was filtered onto 25-mm GF/C glass fiber filters (Whatman, Newton, MA, USA). Each assay tube was rinsed three times with 2 mL PBS. The filters were placed in 3.5 mL Scinti-verse (Fisher, Suwanee, GA, USA), and the radioactivity was counted on a 1211 RackBeta liquid scintillation counter (Wallace-Perkin Elmer, Wellesley, MA, USA).
Receptor-binding assay. RBAs were run using the same per-tube assay volume and the same six RIA PbTx-3 standards. The RBAs were carried out in 12 × 75 mm tubes in binding buffer consisting of 50 mM HEPES (pH 7.4), 130 mM choline chloride, 5.5 mM glucose, 0.8 mM magnesium sulfate, 5.4 mM potassium chloride, 1 mg/mL bovine serum albumin, and 0.01% Emulphor EL 620. Each assay tube contained PbTx-3 standards or blood spot extract (50 µL), [ 3 H]-PbTx-3
(1 nM), and rat brain membrane preparation (80-100 µg protein/mL) in binding buffer (500 µL total volume). Tubes were incubated for 1 hr at 4°C. The membranes were filtered and counted as described above for RIA.
Toxin congener recognition. The RIA and the RBA were used to evaluate toxin congener recognition using PbTx-1, PbTx-2, PbTx-6, and PbTx-9 (Molecular Probes, Inc., Eugene, OR, USA). Caribbean ciguatoxin (CCTX-1) was provided by R. Dickey (Food and Drug Administration, Gulf Coast Seafood Laboratory, Dauphin Island, AL).
Data analysis. All concentrations and halfmaximal effective concentration (EC 50 ) values were determined using Prism Graph Pad 3.0 (GraphPad Software, Inc., San Diego, CA, USA). Where appropriate, significance values were determined by analysis of variance using JMP statistical software (SAS Institute, Cary, NC, USA).
Results
Using a sheep antibody directed against a PbTx-2-fetuin conjugate, we have developed an immunoassay to analyze blood cards for brevetoxin. In order to facilitate comparison with the RBA, we developed the RIA to be a competitive binding assay, run in solution with separation by filtration. Comparison of standard curves for PbTx-3 revealed high sensitivity for both assays (Figure 1 ). However, there was a significant difference between the RIA and RBA in the calculated EC 50 (p < 0.001). The RIA produces a standard curve for PbTx-3
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with a limit of detection (± SE) of 0.31 ± 0.06 nM and EC 50 = 1.2 ± 0.2 nM (n = 10). Using the RBA, the calculated limit of detection for PbTx-3 was 1.01 ± 0.38 nM and EC 50 = 4.0 ± 1.5 nM (n = 7), which is 3-fold higher than that for the RIA.
We next examined the matrix effect of the blood cards on the RIA and RBA. Dried blood spots collected from control animals were extracted and added to assay tubes containing the PbTx-3 standard curve. The presence of matrix caused a minor reduction in total binding in the RIA (11%) and RBA (15%), with no apparent effect on relative affinity (Figure 2) .
We next examined toxin congener recognition between the two assays. The affinity of the antibody for each toxin was determined by reporting the ratio of PbTx-3 equivalents detected by RBA to those detected by RIA. Three brevetoxin congeners (PbTx-2, PbTx-3, and PbTx-9) showed very comparable affinities for each assay method. However, the RIA had a higher affinity for PbTx-6 and a lower affinity for PbTx-1 (Table 1) . Overall, this comparison of the RBA with the RIA yields a rank order of affinity of PbTx-6 > 3 = 2 = 9 > 1. Unlike the RBA, the RIA did not recognize the CCTX-1 (data not shown).
We next analyzed a sample set from an acute time-course exposure that was identical to the sample set previously analyzed by Fairey et al. (2001) using the microplate receptorbinding assay and LC-MS. Mice were treated IP with a high, sublethal dose of PbTx-3 (180 µg/kg bw), and blood was collected at 0.5, 1, 2, 4, and 24 hr. Blood brevetoxin levels were at mean levels of 36 M at 30 min and maintained levels near 25 nM during the 1-, 2-, and 4-hr time points (Figure 3) . At 24 hr, brevetoxin was still detectable (3.3 nM) at levels significantly different from those in nontreated animals (p = 0.002).
Given that we could still detect brevetoxin in blood a full day after exposure, we analyzed blood brevetoxin exposure after longer durations. Using a sample set collected 2.5 years earlier for experiments described by Gordon et al. (2001) , we extracted the blood and conducted brevetoxin analysis by RIA. Mice (CD-1 rather than ICR strain) were treated with 180 µg/kg bw PbTx-3, and groups of four mice were bled at 0.5, 1, 2, 3, 4, or 7 days. The mean blood brevetoxin value at 0.5 days was 26.0 nM and then decreased to 8.2 nM at 1 day and maintained levels around 1.3 nM until day 3 (Figure 4 ). The brevetoxin was detected in animals 3, 4, and 7 days after treatment; however, these levels did not significantly (p > 0.05) differ from the vehicle-treated animals.
As a final experiment, we examined the dose response for brevetoxin to determine the lowest dose at which we could detect blood brevetoxin levels using blood collection cards and RIA detection. ICR mice were treated with increasing concentrations of PbTx-3 (10-300 µg/kg bw), and their symptoms were recorded by observation over the course of 60 min (Table 2 ). Blood was collected at 60 min and applied to blood collection cards. The lowest observable effect level was 100 µg/kg bw PbTx-3, with the symptoms of hind limb paralysis, chewing, and seizures observed. Three mice in the 200 µg/kg bw group and all four mice in the 300 µg/kg group died within the 60-min trial. All doses of brevetoxin administered were detectable at 1 hr, with significant levels found for the lowest administered dose of 10 µg/kg bw, a dose that was 10-fold lower than the lowest observable effect dose of 100 µg/kg bw ( Figure 5) . Analysis of the blood samples by RIA revealed a linear relationship (r 2 = 0.993) between administered and internal dose ( Figure 6 ).
Discussion
In this article, we have compared an antibodybased assay with an RBA for the detection of brevetoxins from blood collection cards of laboratory mice exposed to brevetoxin. The RIA provides more sensitive detection with minimal interference from residual matrix after extraction of blood from the cards. The RIA allowed detection of brevetoxin at doses 10 times lower than the lowest observable effect level and at times up to 2 days after exposure.
Toxin detection methods are classified as analyses or assays, based on whether a sample value is measured with or without separation of active components. Functional, nonanimal assays for brevetoxins include RBAs, immunoassays (including both solid-phase nonradiometric ELISA and liquid-phase radiometric RIA), and cell-based assays ( Five brevetoxin congeners of approximate microgram weight suspended in methanol were tested in the RBA and RIA and calibrated to PbTx-3 equivalents. The data are reported as ratio of the PbTx-3 equivalents as determined by the RBA versus RIA. The data are provided as ratios rather than traditional ED 50 values because two of the congeners were of too small a mass to be dried and weighed. PbTx-3 exposure (hr) Figure 4 . Blood brevetoxin levels after long-term brevetoxin exposure. Mice were treated with 180 µg/kg bw PbTx-3 IP, and blood was collected from four mice at each time point (0.5, 1, 2, 3, 4, and 7 days). A significant level of brevetoxin, 1.3 nM, could be detected up to 2 days after exposure. Days 3, 4, and 7 all showed detectable brevetoxin, but not in concentrations significantly different than that of the control. Results shown are for four animals at each time point from a single experiment. Results shown are mean ± SE. (RBAs and cell-based assays) or by an antibody (RIA and ELISA). In our previous study (Fairey et al. 2001) , we examined brevetoxin in mouse blood extract by RBA and by analysis by LC-MS. In an effort to maintain similar formats for comparison, we developed an RIA using the same radioligand and separation method as we used in the RBA. The antibody used for this work had previously been used in an ELISA format (Garthwaite et al. 2001 ) RIAs have previously been described for brevetoxins to include two types, based on the brevetoxin conjugate linkage used for antibody production. Baden et al. (1984) prepared a PbTx-3-succinate derivative coupled by amine bond to bovine albumin by carbodiimide condensation and produced antibodies in goats, whereas Levine and Shimizu (1992) prepared a PbTx-2 conjugate coupled via an amide bond to bovine albumin by sodium borohydride reduction and produced antibodies in rabbits. Both conjugation methods link albumin to the C-42 on the K-ring of brevetoxin; however, the chemical linkage differs both in composition and length in the two preparations. Poli et al. (1995) compared the two antibody preparations and found EC 50 values about 10 times lower for the rabbit antibody directed against the PbTx-2 conjugate (0.2 vs. 3.0 ng/mL). To produce the antiserum used in our study, we followed Levine and Shimizu's (1992) method of conjugating PbTx-2 to fetuin. The EC 50 of 1.5 nM for this antibody falls within the range of the previously reported RIAs.
Antisera produced using both conjugation procedures detect the type 2 brevetoxins (PbTx-1, PbTx-7, and PbTx-10) poorly relative to the type 1 brevetoxins (PbTx-2, PbTx-3, PbTx-5, PbTx-6, and PbTx-8). We found that the difference between type 2 and type 1 brevetoxins is approximately 4-fold for our antiserum. The differences range from > 500-fold reported by Levine and Shimizu (1992) , to 100-fold reported by Poli and Hewetson (1992) , to 4.5-fold reported by Baden et al. (1984) . This indicates that the sheep antibody described here shows a lower degree of selectivity for the type 2 backbone of brevetoxins and may be more applicable for detection of toxins containing both backbone structures.
In the first phase of our investigation, we compared this RIA with the RBA using an identical format. We found that the RIA had an EC 50 that was three times lower than the RBA (1.2 nM vs. 4.0 nM). In an earlier comparison of the RIA (goat antibody) and the RBA, Baden et al. (1988) found that the RIA was less sensitive than the RBA (EC 50 of 20 vs. 12 nM). The differences may be due to the format in which the assays were conducted. When comparing the selectivity for brevetoxin congeners between the two assay methods, we found that the differences between the methods for brevetoxin type 1 and type 2 backbones differ by approximately 26-fold, a value consistent with that reported by Baden et al. (1988) . Thus, although the RIA detects both brevetoxin backbone structures, in terms of pharmacologic activity the RIA substantially underestimates the type 2 brevetoxins. This critical difference underlies a major difference in methods based on receptors versus antibodies: receptor-based assays are more closely correlated to animal-based assays and toxicity than are assays based on antibodies (Van Dolah and Ramsdell 2001) .
Biologic monitoring for brevetoxins requires measurement of toxin levels in accessible tissues (e.g., blood, hair, urine, and circulating or accessible cells) in order to assess exposure. Toxicokinetic studies have been conducted using radiolabeled brevetoxin by several routes of administration [oral (Cattet and Geraci 1993) , intravenous (Poli et al. 1990 ), inhalation (Benson et al. 1999) ]; however, only Poli et al. (2000) have quantified brevetoxins in clinical samples after exposure. Poli et al. (2000) examined urine and serum samples from two individuals with neurotoxic shellfish poisoning and found that the urine analysis was positive, but brevetoxins were not detectable in serum because of more rapid clearance from serum and matrix interference of serum. We have applied the blood collection card method for marine toxin analysis to allow monitoring of brevetoxins in whole blood with minimal matrix interference. The extraction of dried blood from cellulose cards with methanol provides an excellent separation because the methanol fixes much of the blood matrix to cellulose while providing high recovery of the toxin. The extracts from control blood have caused a small inhibitory effect in the RBA (Fairey et al. 2001) . We have examined this matrix effect by constructing brevetoxin standard curves in the absence and presence of extracted blood matrix for both the RBA and the RIA. In the RIA we observed an 11% decrease in total binding with the extracted blood matrix and no significant change in EC 50 for brevetoxin. These data indicate that blood may indeed provide the optimal collection fluid for biomonitoring of brevetoxin exposure. Furthermore, blood collection cards provide a simple and effective method of sample collection and storage for both the clinic and the field.
Our first exposure experiment for the brevetoxin RIA of blood cards was a timecourse study designed to reproduce the data obtained by the RBA and LC-MS by Fairey et al. (2001) . Using the RIA, we were able to detect brevetoxin in blood at all time points (0.5, 1, 2, 4, and 24 hr) and for each of the four animals per treatment group. By contrast, NO, not observed more than 60 min after toxin administration. Mice were treated IP with increasing doses of brevetoxin, and observable symptoms were recorded at the earliest onset of occurrence. The observation period was time of injection to 60 min postinjection, at which time the animals were sacrificed for blood collection.
Figure 5. Blood brevetoxin levels after low-dose brevetoxin exposure. Mice were treated with PbTx-3 IP, and blood was collected from all four mice at each dose [0 (control) and 10, 25, 50, 100, 200, 300 µg/kg bw] after 1 hr exposure. The plot of average blood PbTx-3 concentration demonstrates that PbTx-3 can be detected at doses 10 times lower than symptomatic levels (100 µg/kg bw).
Results shown are mean ± SE. PbTx-3 dose (µg/kg bw) Figure 6 . Blood brevetoxin levels after low-dose brevetoxin exposure. The plot of the internal dose versus external dose yields an r 2 value of 0.993. The PbTx-3 concentrations were calculated by subtracting the control value (0 dose) from the mean for duplicate blood spots from one animal.
The results indicate mean ± SE for four animals at each concentration from a single experiment. in our earlier study using a microplate receptor assay (Fairey et al. 2001) , although brevetoxin activity was detectable in all experimental groups, only in the 4.0-hr treatment was brevetoxin detected in all four animals. In this earlier study, the mean brevetoxin level (± SE) measured by the RBA at 4 hr treatment was 25 ± 7 nM, which compares well with that found in the present study measured by RIA, a mean value of 27 ± 7 nM at 4 hr treatment. The similar measurements, yet less consistent brevetoxin detection of the RBA in our earlier report, may be due, at least in part, to the lower reaction volume of the microplate format. We next decided to examine RIA detection of blood cards at longer periods of brevetoxin exposure. In an earlier study (Gordon et al. 2001) , we reported a delayed thermoregulatory response to brevetoxin in mice. This delayed response was persistent hyperthermia, which was distinct from the rapid onset hypothermia commonly reported in response to polyether toxins. At that time, we collected blood from four animals each at the 0.5-, 1-, 2-, 3-, 4-, and 7-day time points. The samples were applied to blood collection cards that were stored 32 months before measurement by RIA. The level of brevetoxins detected by RIA were elevated for 12 hr, were reduced by one-third by 24 hr, maintained a significant level above control by day 2, and were detectable but not at significant levels for days 3, 4, and 7. These findings are consistent with the toxicokinetic study of Cattet and Geraci (1993) , who found that radiolabeled [ 3 H]-PbTx-3 was detectable up to 8 days after oral exposure. Taken together, these findings indicate that nonlethal exposures to brevetoxin may be measurable up to 2 days after exposure using RIA measurement by blood collection cards.
The final exposure we conducted was a dose dependency. The doses chosen ranged from 10 to 300 µg/kg bw PbTx-3, which is 5.5-167% of the maximally tolerable dose (180 µg/kg bw) used for our previous studies (Fairey et al. 2001; Gordon et al. 2001 ). We chose blood measurements for 60 min based on our findings of a plateau value of 25-30 nM for time points between 1 and 12 hr after exposure. Based on observable symptoms, we were able to establish 100 µg/kg bw as the lowest observable effect level. An acute decrease in core body temperature was observable only at 200 µg/kg bw and 300 µg/kg bw. Measurement of blood brevetoxin by RIA revealed a linear relationship between administered and internal dose for the 1-hr exposure. Brevetoxin was measurable by RIA at all tested doses with significant amounts at the lowest dose of 10 µg/kg bw. These results indicate that brevetoxin can be measured from blood collection cards at doses 10 times lower than the dose causing the lowest observable symptoms in mice. Taken together with the finding that blood brevetoxin levels are comparable between 1 and 12 hr, this indicates that biomonitoring of brevetoxin by RIA of blood cards may be feasible at nonsymptomatic exposure levels.
A relevant question exists as to how well the IP dosing of PbTx-3 in mice models the exposure of humans and aquatic species to toxin in algae, toxin released from algae into the water or aerosol, and toxin accumulated in the food web? Preliminary studies in our laboratory with mice given PbTx-3 orally and finfish exposed to K. brevis in aquaria (unpublished data) gave results similar to those reported here. Another potential concern lies in the detection of brevetoxin metabolites. K. brevis is reported to produce brevetoxin congeners 2, 1, and 3 in the ratio of 20:4:1 (Roszell et al. 1989) . The predominantly occurring brevetoxin in algae, PbTx-2, is rapidly reduced to the more stable PbTx-3. Following the neurotoxic shellfish poisoning in New Zealand (Mackenzie et al. 1996; Satake et al. 1996) , four brevetoxin metabolites were described, including a taurine conjugate, an S-cysteine conjugate, and fatty acid esters (Ishida et al. 1996; Morohashi et al. 1995 Morohashi et al. , 1999 Murata et al. 1998 ). Subsequently, Poli et al. (2000) reported brevetoxin activity consistent with metabolites from shellfish from Florida coastal waters, and Plakas et al. (2002) identified these as cysteine conjugates. In addition, Poli et al. (2000) purified the two metabolites and compared their activity by RIA and RBA. The metabolites had activity comparable with PbTx-3 by RIA; however, they had a third less activity by RBA. Thus, RIA is likely to detect the major brevetoxin conjugates found both in algae and shellfish; however, receptorbased assays are necessary for precise toxicity measurement.
In summary, we have found that the RIA is more sensitive and has less matrix effect than does the RBA when detecting PbTx-3 in exposed mice using blood collection cards. Nevertheless, the two assays complement one another well when analyzing different PbTx congeners. The RIA provides detection in blood at brevetoxin exposures well below symptomatic levels and allows detection up to 2 days after exposure. Taken together, these results support the merits of tier-based testing for brevetoxins: antibody methods provide a good screening method, whereas receptorbased methods provide a good toxicity measurement, and LC-MS provides absolute confirmation of toxin congeners.
